First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients

• Published in: Transfusion and apheresis science 2021-06, Vol.60 (3), p.103070-103070, Article 103070
• Main Authors: Bekadja, M.A., Mansour, B., Ouldjeriouat, H., Entasoltan, B., Bouchama, S., Charef, L., Amani, K., Hakiki, N., Bouamama, F., Osmani, S., Brahimi, M., Arabi, A., Bouhass, R., Yafour, N.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Autologous; Benzylamines - pharmacology; Benzylamines - therapeutic use; Biosimilaire; Cells; Cyclams - pharmacology; Cyclams - therapeutic use; Female; Hematopoietic Stem Cell Mobilization - methods; Humans; Lymphoma - drug therapy; Male; Middle Aged; Mobilization; Multiple Myeloma - drug therapy; Peripheral Blood Stem Cells - metabolism; Plerixafor; Stem; Young Adult
• ISSN: 1473-0502; 1878-1683
• DOI: 10.1016/j.transci.2021.103070

Mobilization failure in patients is a major therapeutic concern which makes subsequent ASCT impossible. A new growth factor called Plerixafor (Mozobil®) developed by the pharmaceutical industry (Sanofi-aventis, France), is a chemoreceptor antagonist, CXCR4 type, which disrupts the interaction of SDFI and CXCR4, thereby enhancing the effect of G-CSF mobilization and is especially indicated for mobilization failure. Currently, there is a generic of plerixafor developed by the pharmaceutical industry (Hetero Drugs Ltd, India). The brand name of this medicine is Mozifor®. The objective of this study was to evaluate if generic plerixafor has the same efficacy and safety as originator plerixafor when used with G-CSF in the mobilization of PBSCs for autologous ASCT in multiple myeloma (MM) and lymphoma failure patients. The 32 patients received plerixafor were divided in two groups. The first group concerns the 11 consecutive patients prospectively received generic plerixafor (Mozifor®) in the period between January to July 2020. These were compared with a retrospective control cohort (second group n = 21) who had been treated between 2009 and 2019 with originator plerixafor (Mozobil®). For the Mozifor® group, the mean CD34+ was 4.54x106/kg(1.56-6.79), the median time to achieve an absolute neutrophil count >0.5 G/L was 13 days (range: 8–21). The median time to self-sustained platelet count >20 G/L was 15 days (range: 8–24). For the Mozobil® group, the mean CD34+ was 3.1x106/kg (0.56-8.91) (p=0.86), the median time to achieve an absolute neutrophil count >0.5 G/L was 10 days (range 7–23). The median time to self-sustained platelet count >20 G/L was 13 days (range: 7–29). Our study showed that the generic of plerixafor was practically identical to that of the originator (Mozobil®) with no significant difference (p = 0.52). This study demonstrates the safety and feasibility of mobilization PBSC with generic plerixafor in ASCT in MM and lymphoma. Although these outcomes are encouraging, prospective comparison with other traditional auto-HCT regimens used for patients with MM and lymphoma is warranted.